Ionis Pharmaceuticals, Inc. Increase (Decrease) in Other Current Liabilities
Ionis Pharmaceuticals, Inc. (IONS) reported Increase (Decrease) in Other Current Liabilities of $12.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was -$8.15M, a 354.59% decline year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was $21.00M, a 6207.21% increase year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was -$82.35M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was $84.15M, a 698.37% increase year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2025 was $5.33M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2024 was -$42.99M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2023 was -$5.51M, a 111.79% decline from fiscal 2022.
- Ionis Pharmaceuticals, Inc. increase (decrease) in other current liabilities for fiscal 2022 was $46.70M.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 3 month as first filed | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 6 month as first filed | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $12.85M 10-Q · filed 2026-07-29 | -$69.50M derived: sum of 3 quarters · filed 2026-07-29 | $14.65M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $21.00M 10-Q · filed 2026-04-29 | -$61.35M derived: sum of 2 quarters · filed 2026-04-29 | $22.80M derived: sum of 3 quarters · filed 2026-04-29 | $26.00M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-12-31 | -$82.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.80M derived: sum of 2 quarters · filed 2026-02-26 | $5.00M derived: sum of 3 quarters · filed 2026-07-29 | $5.33M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $84.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $87.35M derived: sum of 2 quarters · filed 2026-07-29 | $87.68M 10-Q · filed 2025-10-29 | $73.35M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $3.54M 10-Q · filed 2026-07-29 | -$10.80M derived: sum of 3 quarters · filed 2026-07-29 | -$257.00K derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $333.00K 10-Q · filed 2026-04-29 | -$14.00M derived: sum of 2 quarters · filed 2026-04-29 | -$3.46M derived: sum of 3 quarters · filed 2026-04-29 | $227.00K derived: sum of 4 quarters · filed 2026-04-29 | ||
| 2024-12-31 | -$14.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.79M derived: sum of 2 quarters · filed 2026-02-26 | -$106.00K derived: sum of 3 quarters · filed 2026-02-26 | -$42.99M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $10.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $14.23M derived: sum of 2 quarters · filed 2025-10-29 | -$28.66M 10-Q · filed 2025-10-29 | -$9.95M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$39.20M 10-Q · filed 2025-07-30 | -$20.49M derived: sum of 3 quarters · filed 2026-02-26 | -$7.14M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | -$42.89M 10-Q · filed 2025-04-30 | -$24.17M derived: sum of 2 quarters · filed 2026-02-26 | -$10.83M derived: sum of 3 quarters · filed 2026-02-26 | -$19.93M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $18.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.06M derived: sum of 2 quarters · filed 2026-02-26 | $22.95M derived: sum of 3 quarters · filed 2026-02-26 | -$5.51M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $13.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.24M derived: sum of 2 quarters · filed 2024-11-06 | -$24.22M 10-Q · filed 2024-11-06 | -$15.79M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-06-30 | -$9.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$37.56M 10-Q · filed 2024-08-01 | -$29.13M derived: sum of 3 quarters · filed 2025-02-19 | -$36.04M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-03-31 | -$28.46M 10-Q · filed 2024-05-07 | -$20.03M derived: sum of 2 quarters · filed 2025-02-19 | -$26.93M derived: sum of 3 quarters · filed 2025-02-19 | $7.76M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2022-12-31 | $8.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $1.52M derived: sum of 2 quarters · filed 2025-02-19 | $36.22M derived: sum of 3 quarters · filed 2025-02-19 | $46.70M 10-K · filed 2025-02-19 | ||
| 2022-09-30 | -$6.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $27.79M derived: sum of 2 quarters · filed 2023-11-02 | $38.26M 10-Q · filed 2023-11-02 | $49.41M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $34.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $45.17M 10-Q · filed 2023-08-09 | $56.31M derived: sum of 3 quarters · filed 2024-02-21 | $51.70M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-03-31 | $10.47M 10-Q · filed 2023-05-03 | $21.62M derived: sum of 2 quarters · filed 2024-02-21 | $17.01M derived: sum of 3 quarters · filed 2024-02-21 | $14.00M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2021-12-31 | $11.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $6.53M derived: sum of 2 quarters · filed 2024-02-21 | $3.52M derived: sum of 3 quarters · filed 2024-02-21 | -$8.38M 10-K · filed 2024-02-21 | ||
| 2021-09-30 | -$4.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$7.62M derived: sum of 2 quarters · filed 2022-11-09 | -$19.53M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$14.91M 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | -$11.90M 10-Q · filed 2022-05-04 | |||||
| 2020-09-30 | $10.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $16.20M derived: sum of 2 quarters · filed 2021-11-03 | $13.20M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $5.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.60M 10-Q · filed 2021-08-04 | -$1.97M 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | -$3.01M 10-Q · filed 2021-05-05 | -$2.56M 10-Q · filed 2020-05-06 | ||||
| 2019-09-30 | $626.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$9.85M derived: sum of 2 quarters · filed 2020-11-04 | $3.91M 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | -$10.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $3.28M 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | $13.76M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |